A Rational Moment: Politics And P-Values Do Not Mix

A Popular Rationalism Rebuttal to The Atlantic’s COVID “Revenge” Thesis. If we want science to exist in America, science must come before politics. It must, therefore, rise above politics.

An essay (“Why RFK Jr.’s Anti-Vaccine Campaign Is Working”), published in The Atlantic, Aug 13, 2025) swaps argument for framing and continues the weaponization of framing in the name of science.

In this rebuttal, we will see:

1. What actually happened (dates, actions, sources).

2. That the article’s thesis rests on loaded premises and motive-imputation, not falsifiable claims.

3. What the best evidence shows and does not show on mRNA vaccines: what the best evidence shows.

4. That the article’s claim that “Lab-leak is a fringe notion” is mischaracterized.

5. That governance ≠ “anti-vaccine”; that HHS is learning how to audit ACIP without gaslighting the public.

6. That we deserve a better standard: endpoint precision, risk-stratification, conflicts, open data. The Atlantic’s mudslinging is a poor substitute.

7. A new bottom line: Kennedy’s position using logic, reason, and science. And The Atlantic confuses these with a fairly overdone trope that lost it power over the minds of the public a long time ago.

The piece opens with a flourish—“COVID revenge,” “anti-vaccine,” “assault”—and then leans on it for 1,800 words. Framing is not evidence. Here is what happened, stripped of adjectives. Robert F. Kennedy Jr. is, in fact, the U.S. Secretary of Health and Human Services (sworn in Feb 13, 2025) (HHS, 2025). On June 9 HHS reconstituted CDC’s ACIP, retiring 17 members and promising new appointments; Kennedy published his rationale the same day. On April 1, Jay Bhattacharya began as NIH Director after a March 25 Senate confirmation (NIH, 2025). In early August, HHS began winding down BARDA mRNA-vaccine contracts, canceling or de-scoping 22 projects (≈$500 M) (AHA, 2025). These are matters of record, not insinuation.

Thesis by epithet

The article rebrands a policy program as a personality disorder (“COVID revenge”). That is textbook motive fallacy: substituting hypothesized psychology for analysis of claims, evidence, and statutes. When a cabinet department retires a federal advisory committee and resets grant priorities, the test is procedural validity and evidentiary coherence—not whether the author admires the principals. ACIP’s overhaul was openly announced with a stated goal (“restore public trust,” reduce conflicts); you can contest the argument, but you don’t get to pretend there isn’t one (ASPA, 2025a).

Conflation, everywhere

The essay repeatedly conflates: (i) being critical of how COVID policy was made with being “anti-vaccine,” (ii) mRNA as a platform with one disease’s vaccines, and (iii) “effective” as a binary rather than endpoint-specific (infection vs. hospitalization vs. death) and time-varying (waning). These are analytic errors, not mere rhetoric.

The literature is unambiguous on intentional endpoint separation and waning. We know that over 95% of people who died “from COVID-19” on ventilators died from sepsis or from bacterial pneumonia. And yet large real-world studies that were supposed to show substantial protection against hospitalization and death are persisting as realistic, unchallenged and uncorrected. Weaker, rapidly waning protection against infection—especially post-Omicron. NEJM North Carolina linked-database suggest durable protection vs. hospitalization/death and marked decline vs. infection over 7–9 months. Yet the actual problem of conflated diagnosis remains unaddressed in those studies.

Per CDC’s MMWR (test-negative design): among previously infected adults, boosters cut hospitalization risk during Omicron ≈68%. Nature Communications (contact-tracing, Geneva), again, with diagnosis conflation unresolved: vaccination alone had “limited” effect on transmission during Omicron; infection-conferred immunity reduced contagiousness more than vaccination did. None of that equals “mRNA doesn’t work”: It means how we diagnose, what we diagnose and how we measure the endpoint you measure matters (Plumb, 2022).

The administration’s position—right or wrong—is explicitly about respiratory-virus upper-airway protection and platform prioritization inside BARDA’s portfolio. You can argue the scientific inference; you cannot say no inference was offered (AHA, 2025).

The safety discourse needs precision, not slogans

Another conflation: either deny safety signals or be “anti-vax.” The strongest evidence base establishes a real, age-/sex-/dose-dependent myocarditis signal after mRNA vaccination, concentrated in males 12–24—rare in absolute terms, but non-zero and policy-relevant. A 2025 systematic review/meta-analysis (active-surveillance studies only) estimates attributable risks ≈10–20 per 100,000 in the highest-risk strata (BNT162b2 dose 2 boys 12–17; mRNA-1273 men 18–24). Risk is orders of magnitude lower outside those strata. Those numbers are the point of risk-stratified guidance, not an argument to abolish vaccination (Kitano et al., 2025).

At the same time, protection against severe outcomes in older/high-risk adults is robust and repeatedly observed across designs and settings (Lin et al., 2022; Mongin et al., 2023). A rational portfolio distinguishes populations and endpoints; a rhetorical one collapses them into a loyalty test.

“Lab-leak is still disputed by those whose reputation depends on it” ≠ “It’s a kook theory”

The article labels lab-leak “highly disputed” as if that discredits it by itself, omitting that U.S. agencies have publicly assessed lab-origin as plausible: DOE (low confidence) and FBI (moderate confidence) have both leaned that way in on-the-record statements (Gordon & Strobel, 2023). Dispute exists; that’s not a synonym for “debunked.” Say the uncertainty out loud.

Governance is not medicine, and “stacked with contrarians” is not a finding

If you claim ACIP is now “stacked with contrarians,” name the appointees, enumerate conflicts, and show how that composition would bias specific votes. Otherwise it’s just labeling. The prior ACIP’s disposition has, for years, raised conflict-of-interest questions in congressional and OIG reporting—Kennedy’s op-ed cites that record, and HHS put the reconstitution on the record June 9. You can argue with the remedy; you cannot erase the documented concern (Kennedy, 2025).

On the BARDA mRNA wind-down: argue on claims, not caricatures

BARDA’s cancellations—roughly $500 M across 22 projects—are consequential. They deserve tight counter-argument, not adjectives. The scientific counter-case is straightforward: mRNA platforms shortened development cycles and saved lives in 2021–2022; they continue to protect well against severe outcomes; platform versatility matters for future threats (Alvarado, 2025). Those are empirical claims that can—and should—be weighed against the administration’s narrower claim about upper-respiratory sterilization failure. Both can be true: excellent for rapid countermeasures and severity reduction; limited for infection-blocking at mucosa without new delivery approaches (Lin et al., 2022). That nuance is absent in the essay.

The standard we should demand (from any administration and any magazine)

A rational health-science discourse does five things the essay does not.

First, it states endpoints precisely and shows time-dependence. Infection ≠ hospitalization ≠ death; 0–60 days post-dose ≠ 6–12 months. The strongest studies already do this (Lin et al., 2022).

Second, it quantifies safety signals with strata, not slogans—and sets risk-benefit by age/sex/comorbidity, not by vibes (Kitano et al., 2025).

Third, it separates platform critique (delivery, durability, mucosal immunity) from blanket platform dismissal; if you want mucosal sterilization, fund intranasal/adjointed or heterologous strategies rather than set fire to the lab. The article never engages that middle. (HHS, for its part, explicitly frames a reallocation away from respiratory mRNA vaccines inside BARDA—not a ban on mRNA in oncology/rare disease (ASPA, 2025b).)

Fourth, it treats lab-origin uncertainty as legitimate scientific ambiguity, not as a rhetorical cudgel (Gordon & Strobel, 2023; Habeshian, 2023).

Fifth, it audits process: conflict policies, open meetings, and data access at ACIP/VRBPAC. If the new ACIP improves transparency and discloses financial ties more rigorously than the prior committee, that’s progress; if it doesn’t, critics should measure and demonstrate the failure rather than predict it by adjective.

Bottom line

The administration’s choices are big and debatable. But the essay does not do the work. It substitutes motive-attribution for claims, refuses to specify endpoints when invoking “effectiveness,” and treats disagreements about process as evidence of anti-vaccine zealotry. A Popular Rationalism standard asks the same questions of everyone: What is the claim? What is the endpoint? What is the time window? What is the stratum? What is the conflict policy? Where is the dataset?

You win arguments at those coordinates—not with epithets.

We don’t see Robert F. Kennedy doing what he is doing to seek revenge, or for any other reason. We see him doing what he is doing because it is his job.

If we want science to exist in America, science must come before politics. It must, therefore, rise above politics. It’s a tall order, and people across many issues cannot see, or perhaps will not allow themselves to see, their own weaponization of science.

The weaponization of science must end. Completely. Kennedy is the right man to insist, as his book on Thimerosal says, “Let the Science Speak”.

References

AHA. (2025). HHS to stop funding mRNA vaccine development under BARDA. American Hospital Association | AHA News. https://www.aha.org/news/headline/2025-08-06-hhs-stop-funding-mrna-vaccine-development-under-barda?utm_source=chatgpt.com

Alvarado, D. (2025, August 6). HHS abandons mRNA vaccine research. BioPharma Dive. https://www.biopharmadive.com/news/kennedy-mrna-vaccines-barda-hhs-cancel-contracts/756953/

ASPA. (2025a, June 9). HHS takes bold step to restore public trust in vaccines by reconstituting ACIP. HHS.Gov. https://www.hhs.gov/press-room/hhs-restore-public-trust-vaccines-acip.html

ASPA. (2025b, August 5). HHS Winds Down mRNA Vaccine Development Under BARDA. HHS.Gov. https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html

Gordon, M. R., & Strobel, W. P. (2023, February 26). Lab Leak Most Likely Origin of Covid-19 Pandemic, Energy Department Now Says. The Wall Street Journal. https://www.wsj.com/articles/covid-origin-china-lab-leak-807b7b0a

Habeshian, S. (2023). FBI director: COVID “most likely” resulted from lab leak. Axios. https://www.axios.com/2023/03/01/fbi-director-covid-origins

Kennedy, R. F., Jr. (2025, June 9). RFK Jr.: HHS Moves to Restore Public Trust in Vaccines. The Wall Street Journal. https://www.wsj.com/opinion/rfk-jr-hhs-moves-to-restore-public-trust-in-vaccines-45495112

Kitano, T., Salmon, D. A., Dudley, M. Z., Saldanha, I. J., Thompson, D. A., & Engineer, L. (2025). Age- and sex-stratified risks of myocarditis and pericarditis attributable to COVID-19 vaccination: A systematic review and meta-analysis. Epidemiologic Reviews, 47(1), 1–11. https://doi.org/10.1093/epirev/mxae007

Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S., Sunny, S.-K., Moore, Z., & Zeng, D. (2022). Effectiveness of covid-19 vaccines over a 9-month period in North Carolina. New England Journal of Medicine, 386(10), 933–941. https://doi.org/10.1056/nejmoa2117128

Mongin, D., Bürgisser, N., Laurie, G., Schimmel, G., Vu, D.-L., Cullati, S., Da Silva Mora, L., Després, L., Dudouit, R., Hirsch, B., Müller, B., Roux, C., Duc, G., Zahnd, C., Caparros, A. U., Falcone, J.-L., Silva, N. M., Goeury, T., Charpilloz, C., … Courvoisier, D. S. (2023). Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-41109-9

NIH. (2025). Jay Bhattacharya begins tenure as 18th director of the National Institutes of Health. National Institutes of Health (NIH). https://www.nih.gov/news-events/news-releases/jay-bhattacharya-begins-tenure-18th-director-national-institutes-health

Plumb, I. D. (2022). Effectiveness of COVID-19 mRNA Vaccination in Preventing... MMWR. Morbidity and Mortality Weekly Report, 71. https://doi.org/10.15585/mmwr.mm7115e2